Adial Pharmaceuticals(ADIL) - 2025 Q3 - Quarterly Results

Financial Results - Adial Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2025, in a press release issued on November 14, 2025[5]. - The report indicates that the financial information is not deemed "filed" under the Securities Exchange Act of 1934, thus limiting liability under certain sections[6]. - The report does not provide specific performance metrics or user data in the available content[5]. - There is no mention of future outlook, product development, market expansion, or mergers and acquisitions in the provided documents[5]. Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol ADIL[3]. - The press release is attached as Exhibit 99.1 to the Current Report on Form 8-K[7]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[4]. - The company is classified as an emerging growth company[4]. - The address of the company's principal executive offices is 4870 Sadler Road, Suite 300, Glen Allen, VA 23060[3]. - Cary J. Claiborne serves as the President and Chief Executive Officer of Adial Pharmaceuticals, Inc.[12].